Abstract
Coronary artery disease (CAD) is a progressive disorder and its risk is best determined using multiple biomarkers and risk factors. Many novel biomarkers have been shown to improve cardiovascular disease risk beyond that of the traditional risk factors, including polygenic risk scores, small very low-density lipoprotein (VLDL), ApoB, triglycerides (TG), non-HDL-c, lipoprotein (a) (Lp(a)), coronary calcium scores, C-reactive protein (CRP), B-type natriuretic peptide (BNP), troponins, and many other novel biomarkers that have been measured using high throughput assays.
© 2018 American Society for Clinical Pharmacology and Therapeutics.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acute Coronary Syndrome / blood
-
Acute Coronary Syndrome / diagnosis*
-
Acute Coronary Syndrome / epidemiology
-
Acute Coronary Syndrome / therapy
-
Cholesterol, LDL / blood*
-
Clinical Decision-Making
-
Coronary Angiography
-
Coronary Artery Disease / blood
-
Coronary Artery Disease / diagnosis*
-
Coronary Artery Disease / epidemiology
-
Coronary Artery Disease / therapy
-
Genetic Markers
-
High-Throughput Screening Assays
-
Humans
-
Inflammation Mediators / blood
-
Natriuretic Peptides / blood
-
Predictive Value of Tests
-
Prognosis
-
Risk Assessment
-
Risk Factors
-
Troponin / blood
Substances
-
Cholesterol, LDL
-
Genetic Markers
-
Inflammation Mediators
-
Natriuretic Peptides
-
Troponin